Loading...
Loading...
HUGE| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1,130.1K |
| Gross Profit | -1,130.1K |
| Operating Expense | 9,298.9K |
| Operating I/L | -9,845.0K |
| Other Income/Expense | -112.6K |
| Interest Income | 272.3K |
| Pretax | -9,957.5K |
| Income Tax Expense | 930.3K |
| Net Income/Loss | -10,887.8K |
FSD Pharma Inc. is a pharmaceutical research and development company with a focus on developing innovative treatments for various medical conditions. The company's lead candidate, FSD-201, is currently in Phase II clinical trials for the treatment of COVID-19. Additionally, the company is working on Lucid-PSYCH, a psychoactive molecule for potential treatment of neuropsychiatric disorders, and Lucid-MS, a patented new chemical entity aimed at preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis.
